CY1107470T1 - Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι - Google Patents

Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι

Info

Publication number
CY1107470T1
CY1107470T1 CY20061100939T CY061100939T CY1107470T1 CY 1107470 T1 CY1107470 T1 CY 1107470T1 CY 20061100939 T CY20061100939 T CY 20061100939T CY 061100939 T CY061100939 T CY 061100939T CY 1107470 T1 CY1107470 T1 CY 1107470T1
Authority
CY
Cyprus
Prior art keywords
proteins
leptin
compositions
glycosylated
methods
Prior art date
Application number
CY20061100939T
Other languages
English (en)
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1107470T1 publication Critical patent/CY1107470T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με συνθέσεις γλυκοσυλιωμένης λεπτίνης και με σχετικές μεθόδους. Περιλαμβάνονται γλυκοσυλιωμένες πρωτεΐνες λεπτίνης που έχουν ακτίνα Stokes που εκχωρεί βελτιωμένες ιδιότητες, όπως επίσης και γλυκοσυλιωμένες πρωτεΐνες λεπτίνης που έχουν επιλεγμένες θέσεις για γλυκοσυλίωση, νουκλεϊκά οξέα που κωδικοποιούν αυτές τις πρωτεΐνες, σχετικά κύτταρα-ξενιστές, φορείς, διαδικασίες παραγωγής, και μέθοδοι χρήσεις αυτών των συνθέσεων. Παρέχονται επίσης πρωτότυπες μέθοδοι παραγωγής γλυκοσυλιωμένων πρωτεϊνών. Η γλυκοσυλιωμένη πρωτεΐνη λεπτίνης μπορεί να χρησιμοποιηθεί στην παρασκευή φαρμακευτικής σύνθεσης που μπορεί να χρησιμοποιηθεί στην θεραπευτική αγωγή ανθρώπου για πάθηση που επιλέγεται από παχυσαρκία, διαβήτη και υψηλό περιεχόμενο λιπιδίων αίματος.
CY20061100939T 1999-02-12 2006-07-07 Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι CY1107470T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12
EP00911784A EP1151102B1 (en) 1999-02-12 2000-02-11 Glycosylated leptin compositions and related methods

Publications (1)

Publication Number Publication Date
CY1107470T1 true CY1107470T1 (el) 2012-12-19

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100939T CY1107470T1 (el) 1999-02-12 2006-07-07 Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι

Country Status (11)

Country Link
EP (1) EP1151102B1 (el)
JP (1) JP4841037B2 (el)
AT (1) ATE323766T1 (el)
AU (1) AU781460B2 (el)
CA (1) CA2359840C (el)
CY (1) CY1107470T1 (el)
DE (1) DE60027409T2 (el)
DK (1) DK1151102T3 (el)
ES (1) ES2257287T3 (el)
PT (1) PT1151102E (el)
WO (1) WO2000047741A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2459015A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
ATE475094T1 (de) * 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
JP4809227B2 (ja) 2003-09-26 2011-11-09 メルク セローノ ソシエテ アノニム タンパク質の産生に使用するためのリーダー配列
EP2586456B1 (en) * 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
CA2813038C (en) 2010-09-28 2021-12-28 Amylin Pharmaceuticals, Llc Highly soluble leptins
KR102434075B1 (ko) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CN104822374A (zh) 2012-09-27 2015-08-05 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
PL3074033T3 (pl) 2013-11-26 2019-08-30 The Children's Medical Center Corporation Związki do leczenia otyłości i sposoby ich zastosowania
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
IL192290A0 (en) * 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
ES2339846T3 (es) * 1995-11-22 2010-05-26 Amgen Inc. Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
WO1997026916A1 (en) * 1996-01-25 1997-07-31 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
WO1998007446A1 (en) * 1996-08-23 1998-02-26 Eli Lilly And Company Protein formulations
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
DE69921486T2 (de) * 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
CA2359840A1 (en) 2000-08-17
EP1151102A1 (en) 2001-11-07
WO2000047741A1 (en) 2000-08-17
CA2359840C (en) 2012-10-23
PT1151102E (pt) 2006-07-31
JP2002536018A (ja) 2002-10-29
AU3362300A (en) 2000-08-29
JP4841037B2 (ja) 2011-12-21
DE60027409T2 (de) 2007-04-12
EP1151102B1 (en) 2006-04-19
ATE323766T1 (de) 2006-05-15
DK1151102T3 (da) 2006-05-29
AU781460B2 (en) 2005-05-26
ES2257287T3 (es) 2006-08-01
DE60027409D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
CY1107470T1 (el) Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
DE60307701D1 (de) Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
DE69533544D1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
EP1832599A3 (en) Albumin fusion proteins
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
DK1904635T3 (da) Glycosyleret IL-7, fremstilling og anvendelser
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
CA2031430A1 (en) Process for refolding recombinantly produced tgf-.beta.-like proteins
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
DE69736158D1 (de) Glutamine: Fructose-6-Phosphat Amidotransferase (GFAT), ihre Herstellung und Verwendung
EP1801123A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
EP1506233B1 (en) Active complex of alpha-lactalbumin (hamlet) and cofactor
FI964186A (fi) Ei-liittävät gp350/220-variantit